Transforming growth factor-beta receptor 1 (TGFBR1) and Transforming growth factor-beta receptor 2 (TGFBR2) (TGFBR1/2)

Transforming growth factor-beta receptors 1 and 2 (TGFBR1 and TGFBR2) are essential components of the TGF-beta signaling pathway, functioning as a heterotetrameric transmembrane complex [UniProt: P36897, P37173]. Upon ligand binding, TGFBR2 phosphorylates and activates TGFBR1, which then propagates the signal by phosphorylating SMAD2 and SMAD3 proteins to regulate gene transcription [PMID: 28232556]. These receptors are critical regulators of diverse cellular processes, including cell growth, differentiation, apoptosis, and the production of extracellular matrix. In oncology, the TGFBR1/2 complex exhibits a context-dependent role, acting as a tumor suppressor in early-stage disease but promoting metastasis and immune suppression in advanced cancers [PMID: 30635916]. Beyond cancer, overactivation of these receptors is a primary driver of fibrotic diseases and certain cardiovascular conditions like Loeys-Dietz syndrome. Pharmacological targeting of TGFBR1/2 primarily involves small molecule kinase inhibitors that compete with ATP at the TGFBR1 catalytic site, though clinical use is often limited by toxicities such as heart valve dysfunction and skin lesions [PMID: 29128177].

Other names

ALK-5SKR4TGFR-1TGFbeta-RIITGFR-2Activin receptor-like kinase 5TGF-beta receptor type ITGF-beta receptor type II

ATP-competitive inhibition of the TGFBR1 kinase domain and inhibition of the heterotetrameric receptor complex formation [PMID: 28232556]